Rheumatology, S.Pietro FBF Hospital, via Cassia 600, 00189 Rome, Italy.
Arch Orthop Trauma Surg. 2011 Jan;131(1):139-47. doi: 10.1007/s00402-010-1165-5. Epub 2010 Aug 10.
Osteoarthritis (OA) is a disease of synovial joints and is the most common cause of chronic pain. Viscosupplementation (VS) with hyaluronic acid (HA) is largely used for knee osteoarthritis therapy but the evidence for its usefulness in ankle osteoarthritis is limited. The objective of this review is to assess the efficacy of viscosupplementation treatment of ankle osteoarthritis in the current literature.
The following databases were searched: Medline (period 2006-2008), Database of Abstract on Reviews and Effectiveness and Cochrane Database of Systematic Reviews. Reference lists of relevant articles were controlled for additional references. The search terms Review, Viscosupplementation (VS), Osteoarthritis (OA), Hyaluronic acid (HA), Hyaluronan, Sodium hyaluronate, Ankle OA, Ankle joint were used to identify all studies relating to the use of VS therapy for the ankle OA. Methodological quality of included studies was assessed by assigning level of evidence as previously defined by the Centre for Evidence Based Medicine (CEBM).
Seven articles concerning the efficacy of a total of 275 patients undergoing VS treatment for ankle OA were included. One European study, one Taiwanese study, one Italian study, one Turkish study and three American studies with level of evidence ranging from I to IV evaluated the following products: Hyalgan, Synvisc, Supartz, Adant.
Viscosupplementation is used widely in knee OA and is included in the professional guidelines for treatment of the disease in this joint. The potential for treating osteoarthritis of the ankle joint by viscosupplementation has been suggested in the literature, however, no dosing studies have been published to date, and dosing in the ankle joint remains an area for discussion. Viscosupplementation could potentially provide an useful alternative in treating such patients with painful ankle OA.
骨关节炎(OA)是一种滑膜关节疾病,是慢性疼痛的最常见原因。透明质酸(HA)的粘性补充(VS)主要用于膝关节骨关节炎的治疗,但在踝关节骨关节炎中的有效性证据有限。本综述的目的是评估当前文献中粘性补充治疗踝关节骨关节炎的疗效。
检索了以下数据库:Medline(2006-2008 年期间)、疗效评价和 Cochrane 系统评价数据库。控制相关文章的参考文献列表以获取其他参考文献。使用“Review、Viscosupplementation(VS)、Osteoarthritis(OA)、Hyaluronic acid(HA)、Hyaluronan、Sodium hyaluronate、Ankle OA、Ankle joint”等搜索词来识别所有与 VS 治疗踝关节 OA 相关的研究。根据之前由循证医学中心(CEBM)定义的证据水平,对纳入研究的方法学质量进行评估。
共纳入了 7 篇关于 275 例接受 VS 治疗的踝关节 OA 患者疗效的文章。1 项欧洲研究、1 项台湾研究、1 项意大利研究、1 项土耳其研究和 3 项美国研究的证据水平从 I 级到 IV 级评估了以下产品:Hyalgan、Synvisc、Supartz、Adant。
粘性补充剂广泛用于膝关节 OA,并且包含在该关节疾病治疗的专业指南中。通过粘性补充剂治疗踝关节骨关节炎的潜力在文献中已有提及,但是,迄今为止尚未发表剂量研究,踝关节的剂量仍然是一个讨论领域。粘性补充剂可能为治疗患有疼痛性踝关节 OA 的此类患者提供一种有用的替代方法。